NeuroThera Labs Initiates Phase IIb Clinical Trial Site at Yale Child Study Center for Tourette Syndrome Candidate

Toronto, Ontario — August 5, 2026 — Leads & Copy — NeuroThera Labs Inc., a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd., announced the initiation of its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera’s proprietary cannabinoid-based drug candidate, for the treatment of Tourette Syndrome (TS) in adults.

The trial is now progressing at the Yale Child Study Center, identified as one of the study’s key clinical sites. SCI-110 is an innovative dosage form that combines dronabinol with palmitoylethanolamide, an endocannabinoid-like compound. The combination is designed to reduce tics and associated comorbid symptoms in adults with TS while aiming to minimize side effects.

In addition to the Yale site, the Phase IIb trial is also underway at Hannover Medical School in Hanover, Germany, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. This multi-national approach underscores the global development program for SCI-110.

Dr. Adi Zuloff-Shani, Chief Technology Officer of NeuroThera, highlighted the significance of the U.S. site initiation, stating, “Launching a U.S. site at the Yale Child Study Center represents a significant milestone in our global development program for SCI-110. TS remains a major unmet medical need with limited therapeutic options, particularly in adults who continue to experience persistent, severe, and often debilitating symptoms. We believe SCI-110 has the potential to introduce a novel, more effective and safer treatment approach. We are deeply committed to advancing this promising therapy and generating meaningful clinical data to support its future regulatory approval.”

The Phase IIb study builds upon the positive safety and efficacy results observed in the Phase IIa study, which demonstrated an average tic reduction of 21% across all participants. This reduction was measured using the Yale Global Tic Severity Scale Total Tic Score, considered the gold standard for such assessments. The current Phase IIb study is designed as a randomized, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy, safety, and tolerability of daily oral SCI-110.

The trial will enroll patients aged 18 to 65 who will be randomized to receive either SCI-110 or a placebo. The primary efficacy endpoint will be the change in tic severity, measured by the Yale Global Tic Severity Scale, at weeks 12 and 26 compared to the baseline. Safety will be assessed through ongoing monitoring of adverse events.

NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Source: NeuroThera Labs Inc.